Revvity Reports Q3 2026 Financial Results

11/3/2026
Impact: 68
Healthcare

Revvity reported third-quarter 2026 revenue of $728.9 million, above the FactSet consensus estimate of $694.7 million. Adjusted EPS was $1.38, beating the $1.30 analyst estimate. The company updated its 2026 guidance to approximately $2.86 billion in revenue and adjusted EPS of $5.40 to $5.45, compared with FactSet estimates of $2.85 billion and $5.36, respectively.

AI summary, not financial advice

Share: